Canopy's Fat-Reduction Drug CBL-514 Gets US FDA Go-Ahead for Second Pivotal Phase 3 Trial

AI Summary (NQ-processed)

Canopy Biosciences announced that its IND application for the second multi-national, multi-center pivotal Phase 3 clinical trial (CBL-0302) of its new drug CBL-514 injection, intended for reducing abdominal subcutaneous fat, has passed the US FDA's 30-day review period. The company will now initiate the CBL-0302 trial, which plans to enroll approximately 320 subjects in the US, Canada, and Australia.